Name: UMIN ID:
Unique ID issued by UMIN | C000000157 |
---|---|
Receipt number | R000000227 |
Scientific Title | Phase III Randomized Study of Induction Therapy Comparing Daunorubicin With Idarubicin Followed By Consolidation Therapy Comparing High-Dose Cytarabine With Sequential Multiagent Chemotherapy in Patients With Previously Untreated De Novo Acute Myeloid Leukemia (JALSG AML201 Study) |
Date of disclosure of the study information | 2005/09/12 |
Last modified on | 2011/09/09 10:02:37 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2005/09/11 08:21:39 | ||
2 | Update | 2005/11/11 00:41:09 | Organization Organization Division name Division name |
|
3 | Update | 2005/11/11 00:42:19 | Public title Public title Acronym Acronym |
|
4 | Update | 2005/11/11 00:46:35 | Name of person sending information Name of person sending information Institute |
|
5 | Update | 2006/03/24 18:24:48 | Recruitment status |
|
6 | Update | 2006/09/21 06:39:29 | Homepage URL |
|
7 | Update | 2007/09/11 09:16:19 | Publication of results |
|
8 | Update | 2009/03/25 07:10:55 | Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
9 | Update | 2010/03/11 09:10:24 | Acronym Acronym |
|
10 | Update | 2010/03/11 09:11:37 | Recruitment status |
|
11 | Update | 2011/03/08 14:25:41 | Publication of results |
|
12 | Update | 2011/03/08 14:29:04 | Other related information Other related information |
|
13 | Update | 2011/09/09 10:02:37 | Post marketing survey by drug manufacture etc., specified by Japanese law. |